Key result
Rheumatoid factors, ACPA, and anti-CarP antibodies precede RA development with distinct diagnostic and prognostic roles.
Why the study?
While RF and ACPA have a known synergic effect in predicting RA development and erosive phenotypes, controversies remain regarding the additive value of anti-CarP antibodies.
What is the clinical utility of rheumatoid factor, anti-citrullinated protein antibodies, and anti-carbamylated protein antibodies in the diagnosis, prognosis, and treatment response of rheumatoid arthritis?
What is the clinical utility of rheumatoid factor, anti-citrullinated protein antibodies, and anti-carbamylated protein antibodies in the diagnosis, prognosis, and treatment response of rheumatoid arthritis?
This review highlights the distinct and synergistic roles of RF, ACPAs, and anti-CarP antibodies in the early diagnosis, prognosis, and treatment response prediction of rheumatoid arthritis.
This is the authors' abstract. We don't add key points for this paper.
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease mainly involving synovial inflammation and articular bone destruction. RA is a heterogeneous disease with diverse clinical presentations, prognoses and therapeutic responses. Following the first discovery of rheumatoid factors (RFs) 80 years ago, the identification of both anti-citrullinated protein antibodies (ACPAs) and anti-carbamylated protein antibodies (anti-CarP Abs) has greatly facilitated approaches toward RA, especially in the fields of early diagnosis and prognosis prediction of the disease. Although these antibodies share many common features and can function synergistically to promote disease progression, they differ mechanistically and have unique clinical relevance. Specifically, these three RA associating auto-antibodies (autoAbs) all precede the development of RA by years. However, while the current evidence suggests a synergic effect of RF and ACPA in predicting the development of RA and an erosive phenotype, controversies exist regarding the additive value of anti-CarP Abs. In the present review, we critically summarize the characteristics of these autoantibodies and focus on their distinct clinical applications in the early identification, clinical manifestations and prognosis prediction of RA. With the advancement of treatment options in the era of biologics, we also discuss the relevance of these autoantibodies in association with RA patient response to therapy.
Answers are grounded in this paper and cite their sources.
May aid early RA diagnosis and prognosis via autoantibody profiling; leaves open prospective validation for treatment algorithms.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) conducted a review in Rheumatoid arthritis. Autoantibodies (RF, ACPA, anti-CarP Abs) was evaluated. Rheumatoid factors, anti-citrullinated protein antibodies, and anti-carbamylated protein antibodies precede RA development and have distinct clinical applications in early diagnosis and prognosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: